Enhanced Permeability and Retention effect

Revision as of 02:15, 9 August 2012 by WikiBot (talk | contribs) (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

WikiDoc Resources for Enhanced Permeability and Retention effect

Articles

Most recent articles on Enhanced Permeability and Retention effect

Most cited articles on Enhanced Permeability and Retention effect

Review articles on Enhanced Permeability and Retention effect

Articles on Enhanced Permeability and Retention effect in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Enhanced Permeability and Retention effect

Images of Enhanced Permeability and Retention effect

Photos of Enhanced Permeability and Retention effect

Podcasts & MP3s on Enhanced Permeability and Retention effect

Videos on Enhanced Permeability and Retention effect

Evidence Based Medicine

Cochrane Collaboration on Enhanced Permeability and Retention effect

Bandolier on Enhanced Permeability and Retention effect

TRIP on Enhanced Permeability and Retention effect

Clinical Trials

Ongoing Trials on Enhanced Permeability and Retention effect at Clinical Trials.gov

Trial results on Enhanced Permeability and Retention effect

Clinical Trials on Enhanced Permeability and Retention effect at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Enhanced Permeability and Retention effect

NICE Guidance on Enhanced Permeability and Retention effect

NHS PRODIGY Guidance

FDA on Enhanced Permeability and Retention effect

CDC on Enhanced Permeability and Retention effect

Books

Books on Enhanced Permeability and Retention effect

News

Enhanced Permeability and Retention effect in the news

Be alerted to news on Enhanced Permeability and Retention effect

News trends on Enhanced Permeability and Retention effect

Commentary

Blogs on Enhanced Permeability and Retention effect

Definitions

Definitions of Enhanced Permeability and Retention effect

Patient Resources / Community

Patient resources on Enhanced Permeability and Retention effect

Discussion groups on Enhanced Permeability and Retention effect

Patient Handouts on Enhanced Permeability and Retention effect

Directions to Hospitals Treating Enhanced Permeability and Retention effect

Risk calculators and risk factors for Enhanced Permeability and Retention effect

Healthcare Provider Resources

Symptoms of Enhanced Permeability and Retention effect

Causes & Risk Factors for Enhanced Permeability and Retention effect

Diagnostic studies for Enhanced Permeability and Retention effect

Treatment of Enhanced Permeability and Retention effect

Continuing Medical Education (CME)

CME Programs on Enhanced Permeability and Retention effect

International

Enhanced Permeability and Retention effect en Espanol

Enhanced Permeability and Retention effect en Francais

Business

Enhanced Permeability and Retention effect in the Marketplace

Patents on Enhanced Permeability and Retention effect

Experimental / Informatics

List of terms related to Enhanced Permeability and Retention effect


The Enhanced Permeability and Retention (EPR) effect is the property by which certain sizes of molecules, typically liposomes or macromolecular drugs, tend to accumulate in tumor tissue much more than they do in normal tissues1,2,3. The general explanation that is given for this phenomenon is that, in order for tumor cells to grow quickly, they must stimulate the production of blood vessels (VEGF).Tumor cell aggregates of size as small as 150-200 um, start to become dependent on blood supply carried out by neovasculature for their nutritional and oxygen supply . This newly formed tumor vessels are usually abnormal in form and architecture. They are poorly aligned defective endothelial cells with wide fenestration, lacking smooth muscle layer, or inervation with wider lumen, and impaired functional receptors for angiotensin II. Furthermore, tumor tissues usually lack effective lymphatic drainage . All these factors will lead to abnormal molecular and fluid transport dynamics especially for macromolecular drugs. Namely, this phenomenon was coined “enhanced permeability and retention (EPR)-effect” of macromolecules and lipids in solid tumors . The EPR-effect is even more enhanced by great many pathophysiological factors involved in enhancement of extravasation of macromolecules in solid tumor tissues. For instance, bradykinin, nitric oxide / peroxynitrite, prostaglandins, vascular permeability factor (also known as vascular endothelial growth factor VEGF), tumor necrosis factor and others .

1. Matsamura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanisms of tumoritropic accumulation of protein and the antitumor agent SMANCS. Cancer Res., 46: 6387-6392, 1986.

2. Duncan R., Sat Y-N. Tumour targeting by enhanced permeability and retention (EPR) effect. Ann. Oncol., 9 (Suppl.2): 39 1998

3. Vasey P. A., Kaye S. B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A. H., Murray L. S., Hilditch T. E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res., 5: 83-94, 1999 Category; Molecules


Template:WH Template:WikiDoc Sources